Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12141974 | 0.92 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1NPSR1KDM4EMAPT | |
| SCHEMBL22019205 | 0.84 | HPGD (0.46) | ALDH1A1NPSR1KDM4EHTTLMNA | |
| SCHEMBL12844486 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1NPSR1KDM4EMAPT | |
| SCHEMBL24135776 | 0.81 | ALOX5AP (0.47) | — | |
| SCHEMBL9631669 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1NPSR1KDM4EMAPT | |
| SCHEMBL855339 | 0.77 | POLB (0.60) | SMN1; SMN2ALDH1A1NPSR1KDM4EMAPT | |
| SCHEMBL30073359 | 0.77 | POLB (0.60) | SMN1; SMN2ALDH1A1NPSR1KDM4EMAPT | |
| SCHEMBL12844504 | 0.77 | NPSR1 (0.58) | SMN1; SMN2ALDH1A1NPSR1KDM4EMAPT | |
| SCHEMBL12775471 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1NPSR1KDM4EMAPT | |
| SCHEMBL6984881 | 0.75 | GRM4 (0.54) | SMN1; SMN2ALDH1A1NPSR1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683285-B2 | Modulators of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200157085-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157085-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | SMN1; SMN2 1769/4885ALDH1A1 3168/4885NPSR1 4493/4885 |
| US-10683285-B2 | Modulators of hemoglobin | HBG1, HBG2, HBB | SMN1; SMN2 1769/4885ALDH1A1 3168/4885NPSR1 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.